B-CELL LYMPHOMA

This study looks at the long-term safety of the drug pirtobrutinib in people with certain blood cancers, like chronic lymphocytic leukemia or non-Hodgkin lymphoma. It is for those who completed an earlier study and are still benefiting from the treatment. Participants will receiv…

This early-phase study tests a universal (donor-derived) CAR-T cell therapy called UWD-CD19 for people with B-cell lymphoma or leukemia that has not responded to standard treatments. About 30 participants will receive a single infusion of these cells after chemotherapy to see if …

This study tests a combination of two targeted drugs, palbociclib and ibrutinib, in people with mantle cell lymphoma that has been treated before but returned. The goal is to see if the combination can control the cancer for longer. About 39 adults will take the drugs in 28-day c…

This early-phase study tested a new treatment for people with B-cell lymphoma or leukemia that returned after standard therapy. Researchers took patients' own immune cells (T cells), added a special receptor to help them recognize and attack cancer cells, and infused them back. T…

This early-phase trial tests a new drug, loncastuximab tesirine, added to a standard chemotherapy regimen (DA-EPOCH-R) for people with previously untreated aggressive B-cell lymphomas. The main goal is to find the safest dose and see how well the combination is tolerated. The stu…

This early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL). About 23 adults with CD22-positive B-ALL that has come back or not responded to treatment will receiv…

This early-stage study tests an experimental pill called LOXO-338 in people with advanced blood cancers (like certain leukemias, lymphomas, and multiple myeloma) who have already tried standard treatments. The main goals are to find the safest dose and to see if the drug can shri…

This study aimed to see if the drug glofitamab could stop large B-cell lymphoma from coming back in patients who were in complete remission but still had tiny traces of cancer (minimal residual disease). The trial was withdrawn before enrolling anyone, so no results are available…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests whether the drug anakinra can prevent or reverse severe side effects from CAR-T cell therapy, a powerful cancer treatment. About 62 adults with certain B-cell cancers (like leukemia or lymphoma) will receive anakinra alongside their CAR-T cells. The goal is to re…

This study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infecti…

This study looks at whether a blood test that tracks cancer DNA (called a liquid biopsy) can predict if lymphoma will come back within 1-2 years after initial treatment. Researchers will compare this test to the standard PET scan in 108 adults with B-cell or Hodgkin lymphoma. The…

This study follows about 150 people who have already received Caribou cell therapy for blood cancers like lymphoma or leukemia. The goal is to track any long-term side effects for up to 15 years after treatment. No new treatments are given—just regular check-ups to monitor safety…